Summary

U.S. Glucagon Delivery Devices Market Growth & Trends

The U.S. glucagon delivery devices market is anticipated to reach USD 781.07 million by 2030, according to a new report by Grand View Research, Inc. It is projected to grow at a CAGR of 8.33% during the forecast period. The major factors contributing to market growth include the increasing prevalence of diabetes in the U.S., leading to a higher demand for emergency treatments for severe hypoglycemia, a condition where glucagon is essential. According to the International Diabetes Federation in 2021, there were about 32.21 million diabetes patients in the country, which are further expected to reach 34.75 million by 2030. Furthermore, advances in technology, particularly in the development of user-friendly delivery devices such as auto-injectors and nasal sprays, are making glucagon more accessible to patients and caregivers, thus boosting market adoption.

The growing awareness about the importance of immediate intervention in hypoglycemia emergencies has led to a greater demand for these devices, as individuals are more inclined to be proactive about emergency preparedness. Healthcare providers are also playing a crucial role by educating patients about the use of glucagon and incorporating these devices into standard diabetes management plans. The increased emphasis on preventing hypoglycemia-related complications has driven more widespread adoption of glucagon delivery devices, contributing to the market growth.

The presence of major market participants and their various strategic initiatives play a significant role in driving the overall growth of the glucagon delivery devices market. Key players in the industry are continuously engaged in activities such as obtaining product approvals, launching new products, forming strategic partnerships, and pursuing mergers and acquisitions. These actions help them stay competitive and address the evolving needs of the market. For instance, in May 2024, Xeris and Beta Bionics announced a global partnership to develop a glucagon product designed for use with proprietary pump technology. This collaboration and licensing agreement focuses on the development and commercialization of a glucagon product that leverages Xeris' XeriSol technology. Both companies plan to integrate this product with Beta Bionics' proprietary bi-hormonal pump and pump systems.

U.S. Glucagon Delivery Devices Market Report Highlights

• In 2023, the injectable devices segment dominated the treatment segment by capturing a share of more than 47.6%.

• The intranasal devices segment is anticipated to grow at the fastest CAGR during the forecast period.

• The retail pharmacies segment held the largest market share in 2023 by capturing a share of about 51.7%.

• The online pharmacies segment is expected to grow at the fastest CAGR from 2024 to 2030.

• Among end use, hospitals and clinics held a majority share of the market in 2023.

• The North America region dominated the global market in 2023.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Device Type
1.2.2. Distribution Channel
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Device type outlook
2.2.2. Distribution channel outlook
2.2.3. End use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. U.S. Glucagon Delivery Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing prevalence of diabetes and hypoglycemia
3.2.1.2. Technological advancements
3.2.1.3. Aging population
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Stringent regulatory approval
3.3. U.S. Glucagon Delivery Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Glucagon Delivery Devices Market: Device Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Glucagon Delivery Devices Market Movement Analysis
4.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by Device Type, 2018 to 2030 (USD Million)
4.4. Injectable Devices
4.4.1. Injectable devices market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Intranasal Devices
4.5.1. Intranasal devices market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Wearable Devices
4.6.1. Wearable devices market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Glucagon Delivery Devices Market: Ulcer Distribution Channel Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Glucagon Delivery Devices Ulcer Market Movement Analysis
5.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Retail Pharmacies
5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Online Pharmacies
5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Hospital Pharmacies
5.7.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Glucagon Delivery Devices Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Glucagon Delivery Devices End Use Market Movement Analysis
6.3. U.S. Glucagon Delivery Devices Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals and Clinics
6.4.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Homecare settings
6.5.1. Homecare settings market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Other End Users
6.6.1. Other end users market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Key company market share analysis, 2023
7.4. Company Position Analysis
7.5. Company Categorization (Emerging Players, Innovators and Leaders
7.6. Company Profiles
7.6.1. Eli Lilly and Company
7.6.1.1. Company overview
7.6.1.2. Financial performance
7.6.1.3. Product benchmarking
7.6.1.4. Strategic initiatives
7.6.2. Novo Nordisk A/S
7.6.2.1. Company overview
7.6.2.2. Financial performance
7.6.2.3. Product benchmarking
7.6.2.4. Strategic initiatives
7.6.3. Xeris Pharmaceuticals, Inc.
7.6.3.1. Company overview
7.6.3.2. Financial performance
7.6.3.3. Product benchmarking
7.6.3.4. Strategic initiatives
7.6.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.6.4.1. Company overview
7.6.4.2. Financial performance
7.6.4.3. Product benchmarking
7.6.4.4. Strategic initiatives
7.6.5. Tandem Diabetes Care, Inc.
7.6.5.1. Company overview
7.6.5.2. Financial performance
7.6.5.3. Product benchmarking
7.6.5.4. Strategic initiatives
7.6.6. Fresenius Kabi USA, LLC.
7.6.6.1. Company overview
7.6.6.2. Financial performance
7.6.6.3. Product benchmarking
7.6.6.4. Strategic initiatives
7.6.7. Zealand Pharma A/S
7.6.7.1. Company overview
7.6.7.2. Financial performance
7.6.7.3. Product benchmarking
7.6.7.4. Strategic initiatives
7.6.8. Amphastar Pharmaceuticals, Inc.
7.6.8.1. Company overview
7.6.8.2. Financial performance
7.6.8.3. Product benchmarking
7.6.8.4. Strategic initiatives